DNA
Price
$9.35
Change
-$0.55 (-5.56%)
Updated
Dec 12, 04:59 PM (EDT)
Capitalization
599.84M
Intraday BUY SELL Signals
IMRX
Price
$6.19
Change
-$0.01 (-0.16%)
Updated
Dec 12, 03:16 PM (EDT)
Capitalization
400.33M
89 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

DNA vs IMRX

Header iconDNA vs IMRX Comparison
Open Charts DNA vs IMRXBanner chart's image
Ginkgo Bioworks Holdings
Price$9.35
Change-$0.55 (-5.56%)
Volume$4.61K
Capitalization599.84M
Immuneering
Price$6.19
Change-$0.01 (-0.16%)
Volume$2.57K
Capitalization400.33M
DNA vs IMRX Comparison Chart in %
DNA
Daily Signal:
Gain/Loss:
IMRX
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
DNA vs. IMRX commentary
Dec 13, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DNA is a Hold and IMRX is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Dec 13, 2025
Stock price -- (DNA: $9.90 vs. IMRX: $6.20)
Brand notoriety: DNA and IMRX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: DNA: 76% vs. IMRX: 70%
Market capitalization -- DNA: $599.84M vs. IMRX: $400.33M
DNA [@Biotechnology] is valued at $599.84M. IMRX’s [@Biotechnology] market capitalization is $400.33M. The market cap for tickers in the [@Biotechnology] industry ranges from $113.14B to $0. The average market capitalization across the [@Biotechnology] industry is $2.21B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

DNA’s FA Score shows that 1 FA rating(s) are green whileIMRX’s FA Score has 0 green FA rating(s).

  • DNA’s FA Score: 1 green, 4 red.
  • IMRX’s FA Score: 0 green, 5 red.
According to our system of comparison, DNA is a better buy in the long-term than IMRX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

DNA’s TA Score shows that 5 TA indicator(s) are bullish while IMRX’s TA Score has 4 bullish TA indicator(s).

  • DNA’s TA Score: 5 bullish, 4 bearish.
  • IMRX’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, DNA is a better buy in the short-term than IMRX.

Price Growth

DNA (@Biotechnology) experienced а +7.49% price change this week, while IMRX (@Biotechnology) price change was -7.32% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.68%. For the same industry, the average monthly price growth was +4.10%, and the average quarterly price growth was +64.61%.

Reported Earning Dates

IMRX is expected to report earnings on Mar 11, 2026.

Industries' Descriptions

@Biotechnology (+0.68% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
DNA($600M) has a higher market cap than IMRX($400M). IMRX YTD gains are higher at: 181.818 vs. DNA (0.815). IMRX has higher annual earnings (EBITDA): -63.7M vs. DNA (-292.97M). DNA has more cash in the bank: 474M vs. IMRX (26.4M). IMRX has less debt than DNA: IMRX (4M) vs DNA (429M). DNA has higher revenues than IMRX: DNA (231M) vs IMRX (0).
DNAIMRXDNA / IMRX
Capitalization600M400M150%
EBITDA-292.97M-63.7M460%
Gain YTD0.815181.8180%
P/E RatioN/AN/A-
Revenue231M0-
Total Cash474M26.4M1,795%
Total Debt429M4M10,722%
TECHNICAL ANALYSIS
Technical Analysis
DNAIMRX
RSI
ODDS (%)
Bullish Trend 2 days ago
85%
N/A
Stochastic
ODDS (%)
Bearish Trend 2 days ago
87%
Bullish Trend 2 days ago
80%
Momentum
ODDS (%)
Bullish Trend 2 days ago
80%
Bearish Trend 2 days ago
90%
MACD
ODDS (%)
Bullish Trend 2 days ago
82%
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
79%
Bearish Trend 2 days ago
90%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
81%
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 15 days ago
89%
Declines
ODDS (%)
Bearish Trend about 1 month ago
86%
Bearish Trend 3 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
81%
Bearish Trend 2 days ago
87%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
83%
View a ticker or compare two or three
Interact to see
Advertisement
DNA
Daily Signal:
Gain/Loss:
IMRX
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
TLAFX13.060.05
+0.38%
Transamerica Large Core ESG R4
JLCFX79.250.22
+0.28%
JHancock Fundamental Large Cap Core R4
RAZAX12.060.03
+0.25%
Russell Inv Multi-Asset Strat A
GLCRX33.09N/A
N/A
Goldman Sachs Large Cap Gr Insghts R
MSDUX16.33-0.10
-0.61%
Morgan Stanley Emerging Mkt ex China I